Journal Club

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

Conclusion: Adding 1 year of durvalumab to BCG induction and maintenance significantly improved disease-free survival versus BCG alone in BCG-naive, high-risk NMIBC (HR 0.68), with a manageable safety profile.